to the New England Eye Center) from Carl Zeiss Meditec and Optovue and serving as a consultant to Regeneron and Genentech. Dr Baumal reports serving as a speaker for Allergan and Genetech, as well as having received compensations from Optovue. Dr Duker reports receiving grants from Carl Zeiss Meditec and Optovue while also serving as a consultant to Carl Zeiss Meditec and Optovue. Dr Duker also reports serving as a consultant to Allergan, Aura Biosciences, Lumenis, Omeros, Santen, Thrombogenics, and Ocudyne; being a stock holder in Hemera Biosciences and Ophthotech; and being on the board of directors of Eleven Biotherapeutics and pSivida Corporation. Dr Fujimoto reports having a personal financial interest in Optovue and also receiving royalties from a patent owned by the Massachusetts Institute of Technology and licensed to Optovue. Dr Fujimoto and Mr Moult report receiving grants from the National Institutes of Health and the Air Force Office of Scientific Research during the conduct of the study. Dr Choi reports receiving grants from the National Institutes of Health during the conduct of the study. No other disclosures are reported.